BCL2 and cancer: As more potent and specific anti-apoptotic BCL2 family inhibitors emerge, continued assessment of their impact on MTA sensitivity will be important not only to identify cancers that can be best treated through combination of BH3 mimetics and MTAs, but also as BH3 mimetics may resensitize cancers to MTA treatment.